Good year-end for Bioiberica in 2009
Bioiberica closed 2009 with a turnover of $152 million and significant growth compared to the previous year. These results indicate that the company is on the right track and heading for a promising future.
Related News
We participated in CPHI 2023 in Barcelona, where we showcased our leadership in scientific research, sustainable development and strategic partnerships for a more resilient future with our portfolio of Active Pharmaceutical and Nutraceutical Ingredients.
They've set up Biovall Heparin Science, a joint pharmaceutical innovation project with an investment of 25 million euros and 20 skilled jobs
Join Bioiberica at stand F130 in Geneva, 9-11 May to discover the company’s latest science and insights driving innovation in the nutraceuticals market.